8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

DEFA14A - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

10-Q - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

10-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

PRE 14A - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stock), series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen

No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to CommenceInvestor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact on PTSD, Depression, Anxiety, Addiction, and ObesityNEW YORK, NY / ACCESSWIRE / May 22, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the complete safety data set from the single dose portion of its Phase 1 trial involving PT00114, its synthesized version of a natural stress-regulating brain peptide. The trial, which included 30 subjects across five cohorts receiving doses up to 1,000 micrograms, reported zero clinically-relevant a

NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating neuropsychiatric disorders. This marks a significant milestone with the enrollment of 30 subjects across five cohorts, receiving doses up to 1,000 micrograms.PT00114 has demonstrated outstanding tolerability with no adverse safety findings, building upon safety validations reported earlier this year. The trial progresses as PT00114 shows potential to transform treatment for anxiety, depression, PTSD, a

Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a talk on PT00114, the company's promising new drug candidate, at the Peptide Based Therapeutic Summit in Boston.Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment," Dr. Slee's talk will focus on the groundbreaking structure of PT00114, designed to efficiently cross the blood-brain barrier and unlock new potential in treating serious neuro-psychiatric conditi

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portionPlans to enroll final two out of five cohorts into the single dose portion of the Phase 1 trial within the next monthNEW YORK, NY / ACCESSWIRE / April 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023."In 2023, Protagenic Therapeutics achieved a significant milestone as we began enrol

Next clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The company has reached another milestone by completing three out of five cohorts of healthy volunteers with PT00114, its synthetic version of the stress-regulating peptide TCAP, in a SAD Phase 1 clinical trial. Notably, PT00114 has shown excellent tolerability with no adverse safety findings during these ongoing Phase 1 studies. With promising preclinical efficacy in anxiety, depression, PTSD, and addiction m

Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ETNEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024.The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of its Q4 and FY 2023, which it plans to publish in its Form 10K to be filed with the SEC that day. On the call, management also plans to discuss the company's outlook for FY 2024, including expectations f

NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This resolves the issue of potential delisting from Nasdaq by May 19, 2024 that the company had been facing.On Tuesday, November 21, 2023, the company received a deficiency letter from Nasdaq stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, because it had not maintained a minimum bid pr

Company Anticipates Reporting Complete Phase I Single Dose Results in AprilNEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced a step forward in its mission to address stress-related neuro-psychiatric disorders. The company has completed the first dose escalation step in the Phase I safety clinical trial for PT00114, its pioneering brain peptide compound. The compound has been extensively tested in models of anxiety, depression, PTSD and addiction before entering its present clinical trial.Key Highlights:Safety Validation: PT00114 has demonstrated safety at a low dose of 125 micrograms in the initial cohort of

SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)

SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)

SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)

SC 13G/A - Protagenic Therapeutics, Inc.\new (0001022899) (Subject)

4 - Protagenic Therapeutics, Inc.\new (0001022899) (Issuer)

Maxim Group initiated coverage of Protagenic Therapeutics with a rating of Buy and set a new price target of $4.00